INTRODUCTION
The treatment of variceal hemorrhage remains a difficult and challenging problem. Most patients stop bleeding either spontaneously or with non-operative management including Pitressin, balloon tamponade and injection sclerotherapy. Some patients however, either continue to bleed, or rebleed after initial control and may require emergency surgical intervention to stop the bleeding. Although portasystemic shunting remains the standard surgical management in this situationa'2'3, there is less agreement as to which shunt is best. The mesocaval shunt has been preferred by some 4'5'6'7'8 because it is felt to leave a lower encephalopathy rate; and discouraged by others 9'1'1a because of its higher thrombosis rate. This report documents our experience with mesocaval and portacaval shunting for refractory variceal bleeding over a 16 year period and examines postoperative mortality, encephalopathy and long term survival.
METHODS
Between 1968 and 1983, 100 patients with biopsy proven cirrhosis and variceal bleeding underwent emergency portasystemic shunting. These were patients who continued to bleed despite medical management including attempted correction of coagulopathy, IV Pitressin, balloon tamponade and injection sclerotherapy; or had early recurrent uncontrolled bleeding. All patients received at least 6 units of blood prior to operation. Those Encephalopathy in survivors was present in 54% of patients, and was similar in portacaval and mesocaval shunt patients. We have previously shown that the mesocaval shunt functions as a total shunt hemodynamically 3 and one would not expect any difference in post-shunt encephalopathy rates. This rate is similar to that reported by others after total shunting1. In 26% of patients encephalopathy interfered with activities of daily living or required hospitalization, but 74% of patients followed had either no encephalopathy (46%) or little disability (28%).
We have not been able to predict the occurrence of "severe" encephalopathy by any pre-op parameter in any of this group of emergency shunted patients, or other groups reported from this institution3 '12. We feel therefore, that there remains an important role for emergency portasystemic shunting in patients who are truly refractory to non-operative therapies to stop their bleeding, and that persistant use of non-surgical therapy in such patients is not warranted.
There remains controversy as to which type of shunt is best suited for emergency portasystemic decompression. The interposition mesocaval shunt was enthusiastically adopted in the 1970's, because of reports suggesting that it had a lower encephalopathy rate5'7'8. A randomized trial in the elective setting did not bear out 9 this claim. There has been only one randomized trial of emergency interposition mesocaval shunting which "favoured portacaval shunting" but the numbers were small and the data influenced by an unexplained high (72%) operative mortality rate in the mesocaval shunt patients, most of whom were Child's class A or B1. Most other authors report far less operative mortality with emergency mesocaval shunting4'5'6'1, and are in close agreement to the rate of 28% in this series. Although we found no difference between this operative mortality and the rate of 33% in the portacaval group, the groups had unequal numbers of Child's class B and C patients. Survival should have been prejudiced against the mesocaval group which had more class C and fewer class B patients. In fact, the mortality rate of Child's C patients was lower in the mesocaval group (36%) than in the portacaval group (57%); but the differences are not significant.
The main disadvantage of the mesocaval shunt is the reported incidence of late shunt thrombosis and variceal rebleeding7'1'31. Although we have studied most patients with early post-operative angiography, we do not have long term radiological follow-up except where clinically indicated. In our mesocaval group however, only 1 of 30 patients who left hospital later rebled from varices; and of 11 patients who had an autopsy, 2 had shunt thrombosis. It does not seem that repeated variceal bleeding after mesocaval shunting has been a major clinical problem and this fact is also borne out by a similar 5 year survival with the portacaval shunted patients.
In summary, we found no significant difference in the operative mortality, long term survival or incidence of encephalopathy between these two types of shunts in 100 patients operated on as an emergency. There are certain situations when a mesocaval shunt is preferable to an end-to-side portacaval shunt. These include patients with intractable ascites, reversal of portal flow, and where technical considerations make portacaval shunting extremely difficult. Where these situations do no exist, our current recommendation would be to do the shunt with which the surgeon has the most experience or which is technically easier in the individual patient. 
